Trial Search Results

GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab

This is randomized Phase 2 research Study of the Safety, Efficacy, and Immune Response of GVAX Pancreas Vaccine (with Cyclophosphamide) and CRS-207 with or without Nivolumab in Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma. We hope to learn whether it is safe to give cyclophosphamide, GVAX pancreas vaccine, CRS-207 and nivolumab to treat people with advanced pancreatic cancer who have received one prior chemotherapy treatment for metastatic cancer (cancer that has spread beyond the pancreas).

Stanford is currently not accepting patients for this trial.

Stanford Investigator(s):

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting